Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging: Revealing the Theranostic Potential of SSTR-and PSMA-Directed Endoradiotherapy

Natalie Hasenauer, Takahiro Higuchi, Barbara Deschler-Baier, Philipp E. Hartrampf, Martin G. Pomper, Steven P. Rowe, Martin Fassnacht, Andreas K. Buck, Rudolf A. Werner

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

We present the case of a 60-year-old man with medullary thyroid carcinoma and hepatic, osseous, and lymph node metastases who underwent peptide receptor radionuclide therapy with 177Lu-DOTATOC. After 2 cycles, 68Ga-DOTATOC PET/CT revealed multiple nonavid lesions. To assess whether the patient would be eligible for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, a PSMA PET/CT was conducted. PSMA PET/CT identified increased PSMA expression in both 68Ga-DOTATOC-avid and nonavid lesions. As such, dual-radiotracer PET/CT may allow for insights into the complexities of tumor heterogeneity in patients with medullary thyroid carcinoma, which may pave the way for subsequent therapeutic algorithms.

Original languageEnglish
Pages (from-to)651-652
Number of pages2
JournalClinical Nuclear Medicine
Volume47
Issue number7
DOIs
Publication statusPublished - Jul 1 2022
Externally publishedYes

Keywords

  • endoradiotherapy
  • medullary thyroid carcinoma
  • PSMA
  • radioligand therapy
  • SSTR
  • theranostics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging: Revealing the Theranostic Potential of SSTR-and PSMA-Directed Endoradiotherapy'. Together they form a unique fingerprint.

Cite this